Ocular Therapeutix Inc (NASDAQ:OCUL) has received a consensus rating of “Buy” from the nine brokerages that are covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $13.67.
OCUL has been the topic of several research analyst reports. Piper Jaffray Companies set a $14.00 price target on shares of Ocular Therapeutix and gave the stock a “buy” rating in a research note on Friday, March 8th. Cantor Fitzgerald restated a “buy” rating and set a $24.00 target price on shares of Ocular Therapeutix in a research report on Thursday, March 7th. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, December 4th. Cowen restated a “buy” rating and set a $13.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, December 4th. Finally, ValuEngine upgraded shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Wednesday, January 2nd.
In related news, Director Richard L. Md Lindstrom bought 56,441 shares of the company’s stock in a transaction on Wednesday, March 13th. The shares were acquired at an average cost of $4.33 per share, for a total transaction of $244,389.53. Following the purchase, the director now directly owns 100,000 shares of the company’s stock, valued at $433,000. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Michael H. Goldstein bought 10,000 shares of the company’s stock in a transaction on Friday, March 15th. The stock was bought at an average price of $4.15 per share, for a total transaction of $41,500.00. The disclosure for this purchase can be found here. Insiders acquired a total of 90,441 shares of company stock worth $385,490 over the last 90 days. Insiders own 15.90% of the company’s stock.
OCUL traded up $0.11 during mid-day trading on Friday, reaching $4.26. 22,163 shares of the company traded hands, compared to its average volume of 552,952. The firm has a market cap of $180.58 million, a PE ratio of -2.71 and a beta of 1.86. The company has a current ratio of 6.14, a quick ratio of 6.11 and a debt-to-equity ratio of 0.69. Ocular Therapeutix has a 52-week low of $3.46 and a 52-week high of $8.28.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Thursday, March 7th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.05). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.45 million. Ocular Therapeutix had a negative net margin of 3,013.97% and a negative return on equity of 136.09%. As a group, research analysts forecast that Ocular Therapeutix will post -1.58 EPS for the current fiscal year.
About Ocular Therapeutix
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
See Also: Cash Flow
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.